|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,361,000 |
Market
Cap: |
722.26(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$15.25 - $15.25 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mchugh Julie |
Director |
|
2022-11-21 |
4 |
D |
$15.25 |
$245,449 |
D/D |
(16,095) |
0 |
|
- |
|
Gryska David W |
Director |
|
2022-11-21 |
4 |
D |
$15.25 |
$30,439 |
I/I |
(1,996) |
0 |
|
- |
|
Gryska David W |
Director |
|
2022-11-21 |
4 |
D |
$15.25 |
$175,299 |
D/D |
(11,495) |
0 |
|
- |
|
Lang Peter Frederick |
Chief Financial Officer |
|
2022-11-21 |
4 |
D |
$15.25 |
$706,029 |
D/D |
(46,297) |
0 |
|
- |
|
Du Toit Michael |
Director |
|
2022-11-21 |
4 |
D |
$15.25 |
$245,449 |
D/D |
(16,095) |
0 |
|
- |
|
Calabrese Jeffrey |
Vice President of Finance |
|
2022-11-21 |
4 |
D |
$15.25 |
$283,421 |
D/D |
(18,585) |
0 |
|
- |
|
Larocca John |
General Counsel |
|
2022-11-21 |
4 |
D |
$15.25 |
$817,171 |
D/D |
(53,585) |
0 |
|
- |
|
Kannan Raj |
Chief Executive Officer |
|
2022-11-21 |
4 |
D |
$15.25 |
$3,290,691 |
D/D |
(215,783) |
0 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2022-11-21 |
4 |
D |
$15.25 |
$4,273,721 |
D/D |
(280,244) |
0 |
|
- |
|
Mcgraw Benjamin F III |
Director |
|
2022-11-21 |
4 |
D |
$15.25 |
$640,256 |
D/D |
(41,984) |
0 |
|
- |
|
Croarkin Richard |
Director |
|
2022-11-21 |
4 |
D |
$15.25 |
$245,449 |
D/D |
(16,095) |
0 |
|
- |
|
Mcdonnell Peter J |
Director |
|
2022-11-21 |
4 |
D |
$15.25 |
$121,924 |
D/D |
(7,995) |
0 |
|
- |
|
Calabrese Jeffrey |
Vice President of Finance |
|
2022-11-01 |
4 |
D |
$15.22 |
$2,724 |
D/D |
(179) |
18,585 |
|
- |
|
Larocca John |
General Counsel |
|
2022-08-14 |
4 |
D |
$11.57 |
$8,920 |
D/D |
(771) |
53,585 |
|
- |
|
Calabrese Jeffrey |
Vice President of Finance |
|
2022-08-14 |
4 |
D |
$11.57 |
$3,066 |
D/D |
(265) |
18,764 |
|
- |
|
Calabrese Jeffrey |
Vice President of Finance |
|
2022-07-01 |
4 |
D |
$8.36 |
$2,224 |
D/D |
(266) |
19,029 |
|
- |
|
Calabrese Jeffrey |
Vice President of Finance |
|
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,276 |
19,295 |
|
- |
|
Mcgraw Benjamin F III |
Director |
|
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,245 |
41,984 |
|
- |
|
Mchugh Julie |
Director |
|
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,245 |
16,095 |
|
- |
|
Mcdonnell Peter J |
Director |
|
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,245 |
7,995 |
|
- |
|
Croarkin Richard |
Director |
|
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,245 |
16,095 |
|
- |
|
Gryska David W |
Director |
|
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,245 |
11,495 |
|
- |
|
Du Toit Michael |
Director |
|
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,245 |
16,095 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2022-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
19,015 |
280,244 |
|
- |
|
Lang Peter Frederick |
Chief Financial Officer |
|
2022-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
46,297 |
46,297 |
|
- |
|
333 Records found
|
|
Page 1 of 14 |
|
|